Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Immersive Sensory Projections for Hospitalized Patients

NCT06577870 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-05-20
Last updated
2026-06-16

Condition(s) studied

Hospitalism

Investigational drug(s) / intervention(s)

Hospitalization in intensive care or continuing care unit

Hospitalization in intensive care or continuing care unit: Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.

Study summary

The purpose of this study is to assess the impact of adding three sensory elements (visual, auditory, olfactory) on reducing discomfort in patients hospitalized in the intensive care unit/continuing care unit.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years ; * Patient hospitalized in intensive care or continuing care unit for an estimated minimum of 48 hours; * Patient hospitalized for a medical indication (including in the pre-surgical phase) or in the post-surgical phase; * Patient or support person who speaks and understands French, has understood the research procedures and is able to complete the questionnaires; * For women of childbearing age (non-menopausal), even for those on contraception: negative pregnancy test (urinary); If positive: completed by a biological test; * Patient or trusted support person having been informed and having signed an informed consent form to participate in the study. Exclusion Criteria: * Deaf or blind patient; * Asthmatic patient with background treatment; * Epileptic patient or known history of convulsion; * Known allergy or intolerance to essential oils or to a component of essential oils; * Patient transferred from another intensive care unit; * Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision); * Breast-feeding or pregnant women; * Patient or support person unable to understand information relating to the study (linguistic, psychological, cognitive, etc.); * Unconscious patient with no relative or support person present; * Homeless patient; * Patient with known severe psychiatric illness such as chronic hallucinatory psychosis or paranoid syndrome; * Patient participating in or being excluded from another clinical trial; * Patient not covered by a social security scheme.

Primary outcome measure(s)

  • REAnimation Patient Discomfort Questionnaire — 2 months
    Overall score on the REAnimation Patient Discomfort Questionnaire at the end-of-study visit

Trial sites (1)

FacilityCityRegionStatus
Hôpital Privé Jacques Cartier Massy France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06577870 on ClinicalTrials.gov ↗ ← All trials in France